This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
amino acid | 970 |
amino acids | 911 |
antimicrobial peptides | 549 |
antimicrobial activity | 305 |
antimicrobial peptide | 284 |
mass spectrometry | 269 |
phage display | 243 |
peptide synthesis | 194 |
membrane fusion | 183 |
binding site | 182 |
secondary structure | 182 |
biological activity | 173 |
solid phase | 167 |
acid residues | 163 |
herpes simplex | 161 |
molecular dynamics | 159 |
active site | 157 |
side chain | 155 |
simplex virus | 155 |
virus type | 145 |
formyl peptide | 145 |
synthetic peptides | 141 |
immune response | 136 |
side chains | 135 |
cell membrane | 133 |
drug delivery | 130 |
peptide receptor | 130 |
spike protein | 130 |
protein interactions | 129 |
fusion proteins | 127 |
crystal structure | 124 |
epithelial cells | 122 |
ms ms | 122 |
immunodeficiency virus | 120 |
escherichia coli | 120 |
cell lines | 118 |
nucleic acids | 115 |
human immunodeficiency | 114 |
respiratory syndrome | 113 |
inhibitory activity | 111 |
antiviral activity | 111 |
filamentous phage | 111 |
affi nity | 109 |
peptide sequences | 109 |
host defence | 108 |
nucleic acid | 106 |
penetrating peptides | 105 |
npy npf | 104 |
negatively charged | 104 |
fusion peptides | 103 |
synthetic peptide | 103 |
peptide sequence | 102 |
acute respiratory | 100 |
important role | 99 |
phase peptide | 99 |
small molecules | 99 |
conformational changes | 99 |
severe acute | 97 |
positively charged | 95 |
influenza virus | 95 |
peptides derived | 95 |
cov cl | 95 |
staphylococcus aureus | 95 |
acid sequence | 94 |
membrane proteins | 94 |
defence peptides | 93 |
cl pro | 93 |
bioactive peptides | 92 |
binding sites | 91 |
immune system | 90 |
circular dichroism | 90 |
present study | 90 |
negative bacteria | 90 |
coiled coil | 90 |
viral fusion | 89 |
cancer cells | 89 |
molecular weight | 89 |
high affinity | 88 |
antibacterial activity | 87 |
cellular uptake | 84 |
binding domain | 83 |
innate immunity | 83 |
spike glycoprotein | 83 |
cell surface | 82 |
naturally occurring | 82 |
fusion protein | 82 |
plasma membrane | 82 |
biologically active | 81 |
nmr spectroscopy | 81 |
peptide libraries | 80 |
cell line | 80 |
mg ml | 80 |
derived peptides | 79 |
terminal region | 79 |
building blocks | 78 |
type receptors | 78 |
cord uid | 78 |
doc id | 78 |
gene expression | 77 |
growth factor | 77 |
fi rst | 76 |
modifi ed | 76 |
protein structure | 76 |
lipid bilayer | 76 |
enveloped viruses | 76 |
antifungal activity | 75 |
wide range | 74 |
fusion peptide | 74 |
peptide inhibitors | 73 |
substrate specificity | 73 |
widely used | 73 |
class ii | 72 |
free energy | 72 |
cell membranes | 72 |
mammalian cells | 71 |
drug discovery | 71 |
clinical trials | 71 |
cyclic peptides | 70 |
gene delivery | 70 |
binding affinity | 68 |
chemical synthesis | 68 |
immune responses | 67 |
room temperature | 67 |
protein folding | 67 |
active peptides | 66 |
terminal domain | 66 |
like particles | 66 |
drug resistance | 66 |
two different | 65 |
peptide binding | 65 |
peptide ligands | 65 |
cell death | 65 |
lipid bilayers | 65 |
wild type | 65 |
signal transduction | 65 |
acid sequences | 65 |
highly conserved | 65 |
recent years | 64 |
monoclonal antibodies | 64 |
serine protease | 64 |
host defense | 64 |
host cell | 63 |
identifi ed | 63 |
may also | 63 |
mouse model | 63 |
phase synthesis | 63 |
peptide derived | 63 |
electron microscopy | 62 |
nervous system | 62 |
peptide arrays | 62 |
cell penetrating | 62 |
two peptides | 62 |
peptides containing | 62 |
hydrogen bonds | 61 |
epitope mapping | 61 |
cleavage site | 61 |
receptor binding | 61 |
innate immune | 61 |
helical structure | 60 |
cell wall | 60 |
fl uorescence | 60 |
host cells | 60 |
membrane protein | 59 |
therapeutic potential | 59 |
disulfide bonds | 59 |
serine proteases | 59 |
small molecule | 59 |
positive bacteria | 57 |
cell adhesion | 57 |
large number | 57 |
dynamics simulations | 57 |
results suggest | 57 |
mg kg | 56 |
effi cient | 56 |
previous studies | 56 |
peptide substrates | 56 |
penetrating peptide | 56 |
disulfide bridges | 56 |
electrostatic interactions | 56 |
cell culture | 56 |
rational design | 56 |
display technology | 55 |
type peptides | 55 |
protein kinase | 55 |
side effects | 54 |
drug design | 53 |
cell proliferation | 53 |
target protein | 53 |
class i | 53 |
crystal structures | 53 |
results obtained | 53 |
ion channels | 53 |
central nervous | 52 |
net charge | 52 |
liquid chromatography | 52 |
wound healing | 52 |
secondary structures | 52 |
modifi cation | 52 |
dendritic cells | 52 |
antifungal peptide | 52 |
purifi cation | 52 |
virus entry | 52 |
peptides may | 51 |
virus infection | 51 |
amyloid fibrils | 51 |
peptide library | 51 |
solid support | 51 |
tandem mass | 50 |
binding protein | 50 |
sars fp | 50 |
like peptides | 50 |
peptide bond | 50 |
viral proteins | 50 |
cyclic peptide | 50 |
ionic strength | 50 |
tumor cells | 50 |
drug development | 50 |
purifi ed | 50 |
results show | 50 |
physicochemical properties | 49 |
conformational change | 49 |
amphibian peptides | 49 |
breast cancer | 49 |
monoclonal antibody | 49 |
specifi city | 49 |
dependent manner | 49 |
gel electrophoresis | 49 |
cationic antimicrobial | 49 |
closely related | 48 |
human beta | 48 |
brain barrier | 48 |
prostate cancer | 48 |
cancer cell | 48 |
commonly used | 48 |
key role | 48 |
hydrogen bonding | 48 |
protease inhibitors | 48 |
intrinsically disordered | 48 |
viral entry | 47 |
activity relationship | 47 |
peptide chain | 47 |
ct peptide | 47 |
protein sequences | 47 |
cleavage sites | 47 |
peptide design | 46 |
tryptic peptides | 46 |
like peptide | 46 |
protein interaction | 46 |
rich peptides | 46 |
short peptides | 45 |
primary structure | 45 |
acid composition | 45 |
structure prediction | 45 |
viral envelope | 45 |
gene therapy | 45 |
sequence similarity | 45 |
type i | 45 |
binding proteins | 44 |
results indicate | 44 |
derived peptide | 44 |
heptad repeat | 44 |
experimental data | 44 |
animal models | 44 |
signifi cant | 44 |
model membranes | 44 |
biological activities | 44 |
acid residue | 44 |
delivery systems | 44 |
stem cells | 44 |
peptide array | 44 |
recent studies | 44 |
ligand binding | 44 |
transcription factors | 44 |
recombinant protein | 44 |
also known | 43 |
head group | 43 |
hydrophobic residues | 43 |
helical conformation | 43 |
high concentrations | 43 |
hydrophobic core | 43 |
peptide nucleic | 43 |
structural analysis | 43 |
protein design | 43 |
present work | 42 |
infl uence | 42 |
viral infection | 42 |
i ri | 42 |
antiviral peptides | 42 |
antimicrobial agents | 42 |
infected cells | 42 |
cell epitopes | 42 |
commercially available | 42 |
charged residues | 41 |
dengue virus | 41 |
enzymatic activity | 41 |
amino group | 41 |
protein sequence | 41 |
therapeutic agents | 41 |
aqueous solution | 40 |
structural studies | 40 |
binding peptides | 40 |
peptide fragments | 40 |
helical peptides | 40 |
containing peptides | 40 |
helical coiled | 40 |
even though | 40 |
kcal mol | 40 |
transcription factor | 39 |
cell fusion | 39 |
performed using | 39 |
protein complexes | 39 |
membrane interactions | 39 |
signaling pathways | 39 |
directed mutagenesis | 39 |
specific antibodies | 39 |
sars ifp | 39 |
also found | 39 |
human neutrophil | 39 |
ms analysis | 38 |
human plasma | 38 |
nt peptide | 38 |
exon skipping | 38 |
modifi cations | 38 |
protecting groups | 38 |
sh domain | 38 |
structural features | 38 |
syndrome coronavirus | 38 |
reverse transcriptase | 38 |
mer rpl | 38 |
endothelial cells | 38 |
cysteine residues | 38 |
hydrophobic amino | 38 |
dimensional structure | 38 |
hydrogen bond | 38 |
protein synthesis | 37 |
magnetic resonance | 37 |
van der | 37 |
mer peptide | 37 |
helix bundle | 37 |
model system | 37 |
muscular dystrophy | 37 |
peptide concentration | 37 |
results showed | 37 |
chemical ligation | 37 |
human diseases | 37 |
three peptides | 37 |
effi ciency | 37 |
liquid crystalline | 37 |
heparan sulfate | 37 |
disulfide bond | 36 |
human cathelicidin | 36 |
venom peptides | 36 |
fatty acyl | 36 |
pore formation | 36 |
new class | 36 |
type ii | 36 |
tertiary structure | 36 |
infectious diseases | 36 |
biological processes | 36 |
human cytomegalovirus | 36 |
peptide analogues | 36 |
paneth cells | 36 |
water molecules | 35 |
transmembrane domain | 35 |
peptide length | 35 |
identifi cation | 35 |
protein binding | 35 |
lipid membranes | 35 |
human neutrophils | 35 |
high resolution | 35 |
type neuropeptides | 35 |
molecular mechanisms | 35 |
unrelated peptides | 35 |
human proteins | 35 |
target proteins | 35 |
protein kinases | 35 |
functional groups | 35 |
high throughput | 35 |
snake venom | 35 |
sars coronavirus | 35 |
signal peptide | 35 |
ng ml | 35 |
structural changes | 35 |
sequence homology | 35 |
hydrophobic interactions | 35 |
viral replication | 35 |
target cells | 35 |
structural information | 35 |
membranotropic peptides | 35 |
peptide conjugates | 35 |
different types | 34 |
protein structures | 34 |
peptide receptors | 34 |
thermal stability | 34 |
platelet aggregation | 34 |
protein engineering | 34 |
full length | 34 |
peptides corresponding | 34 |
activity relationships | 34 |
clinical samples | 34 |
cationic peptides | 34 |
outer membrane | 34 |
fusion process | 34 |
protease activity | 34 |
scorpion venom | 34 |
random coil | 34 |
candida albicans | 34 |
mer peptides | 34 |
novel peptide | 33 |
cell cycle | 33 |
computational methods | 33 |
previously reported | 33 |
ps peptide | 33 |
wide variety | 33 |
biological functions | 33 |
structural characterization | 33 |
peptide substrate | 33 |
ab initio | 33 |
specifi cally | 33 |
blood pressure | 33 |
drug candidates | 33 |
pseudomonas aeruginosa | 33 |
broad range | 33 |
phage library | 33 |
light scattering | 33 |
neurodegenerative diseases | 33 |
formyl peptides | 33 |
bacterial cell | 32 |
peptide microarrays | 32 |
peptide backbone | 32 |
living cells | 32 |
molecular mimicry | 32 |
previously described | 32 |
protein nanoparticles | 32 |
exclusion chromatography | 32 |
first time | 32 |
ray crystallography | 32 |
native chemical | 32 |
bond formation | 32 |
first step | 32 |
tumor growth | 32 |
gene transfer | 32 |
also observed | 32 |
positive charge | 32 |
affinity chromatography | 32 |
complex formation | 32 |
eukaryotic cells | 32 |
well known | 32 |
amide bond | 32 |
coat protein | 32 |
dna binding | 32 |
protein identification | 31 |
molecular mass | 31 |
broad spectrum | 31 |
biological membranes | 31 |
epithelial cell | 31 |
sirna delivery | 31 |
recombinant proteins | 31 |
membrane disruption | 31 |
plasmon resonance | 31 |
inhibitory peptides | 31 |
arginine residues | 31 |
class iii | 31 |
metabolic stability | 31 |
low molecular | 31 |
cell growth | 31 |
natural products | 31 |
high degree | 31 |
multiple sclerosis | 31 |
terminal amino | 31 |
unnatural amino | 31 |
surface plasmon | 31 |
proteins involved | 31 |
aromatic residues | 31 |
peb gf | 31 |
cd spectroscopy | 31 |
fl uorescent | 30 |
delivery system | 30 |
throughput screening | 30 |
novel antimicrobial | 30 |
cell types | 30 |
viral membrane | 30 |
conformational analysis | 30 |
ion channel | 30 |
diffi cult | 30 |
entry inhibitors | 30 |
nuclear magnetic | 30 |
viral peptides | 30 |
laser desorption | 30 |
intracellular delivery | 30 |
nmr studies | 30 |
antimicrobial properties | 30 |
mm tris | 30 |
highly specific | 30 |
model peptides | 30 |
small peptides | 30 |
proteolytic cleavage | 30 |
autoimmune diseases | 30 |
antimicrobial activities | 30 |
molecular basis | 30 |
molecular modeling | 30 |
ser thr | 30 |
critical role | 30 |
oxidative stress | 30 |
biological function | 30 |
molecular mechanism | 29 |
protease cleavage | 29 |
cellular processes | 29 |
filamentous bacteriophage | 29 |
novo design | 29 |
carboxylic acid | 29 |
converting enzyme | 29 |
chain length | 29 |
md simulations | 29 |
size exclusion | 29 |
dehydrogenase type | 29 |
data set | 29 |
amphibian amps | 29 |
peptide amphiphiles | 29 |
transmission electron | 29 |
cd spectra | 29 |
three different | 29 |
crucial role | 29 |
coupled receptors | 29 |
acyl chains | 29 |
coronavirus spike | 29 |
united states | 29 |
endosomal escape | 29 |
molecular level | 29 |
neural networks | 29 |
structural basis | 29 |
much higher | 28 |
angiotensin ii | 28 |
target cell | 28 |
desorption ionization | 28 |
vaccine development | 28 |
molecular interactions | 28 |
molecular docking | 28 |
molar ratio | 28 |
blood cells | 28 |
cell lysates | 28 |
terminal fragment | 28 |
extracellular matrix | 28 |
amyloid formation | 28 |
potent inhibitors | 28 |
nasopharyngeal swabs | 28 |
coupling reagents | 28 |
human cells | 28 |
disease virus | 28 |
defense peptides | 28 |
bacterial infections | 28 |
random peptide | 28 |
hla class | 28 |
sequence alignment | 28 |
neutralizing antibodies | 28 |
may lead | 28 |
sequence analysis | 28 |
der waals | 28 |
type diabetes | 28 |
glutamic acid | 28 |
membrane surface | 28 |
binding properties | 28 |
low concentrations | 28 |
western blotting | 28 |
acid substitutions | 27 |
biological properties | 27 |
specific binding | 27 |
using fmoc | 27 |
md simulation | 27 |
recent study | 27 |
conventional antibiotics | 27 |
single amino | 27 |
small intestine | 27 |
vivo studies | 27 |
life cycle | 27 |
translational modifications | 27 |
metal ions | 27 |
natural amino | 27 |
point mutations | 27 |
reperfusion injury | 27 |
peptides isolated | 27 |
protease inhibitor | 27 |
taken together | 27 |
antibacterial peptide | 27 |
posttranslational modifications | 27 |
isothermal titration | 27 |
peptide classification | 27 |
also demonstrated | 27 |
bone marrow | 27 |
neutralizing activity | 27 |
cell viability | 27 |
hela cells | 27 |
native peptide | 27 |
catalytic domain | 27 |
catalytic activity | 27 |
titration calorimetry | 27 |
protein function | 27 |
linear peptides | 27 |
linker region | 27 |
peptide structure | 27 |
virus glycoprotein | 27 |
signifi cantly | 26 |
light chain | 26 |
display libraries | 26 |
substrate binding | 26 |
synthesized peptides | 26 |
assisted laser | 26 |
coupled receptor | 26 |
take place | 26 |
based approach | 26 |
data bank | 26 |
sample preparation | 26 |
surface area | 26 |
rheumatoid arthritis | 26 |
mm nacl | 26 |
mic values | 26 |
mouth disease | 26 |
lipid membrane | 26 |
modified peptides | 26 |
peptides using | 26 |
poorly understood | 26 |
phage displaying | 26 |
better understanding | 26 |
solution structure | 26 |
protein degradation | 26 |
tof ms | 26 |
type signalling | 26 |
assembling peptide | 26 |
coiled coils | 26 |
antibody fragments | 26 |
pathogenic bacteria | 26 |
functional characterization | 26 |
amino groups | 26 |
least two | 26 |
chemokine receptor | 26 |
envelope protein | 26 |
cell entry | 26 |
high affi | 26 |
hydroxysteroid dehydrogenase | 26 |
proteolytic enzymes | 25 |
residue peptide | 25 |
aspartic acid | 25 |
machine learning | 25 |
steric block | 25 |
least one | 25 |
inflammatory response | 25 |
lysine residues | 25 |
linear peptide | 25 |
hydrophobic thickness | 25 |
binding motif | 25 |
recent advances | 25 |
protein complex | 25 |
potential therapeutic | 25 |
opioid receptor | 25 |
ang ii | 25 |
short peptide | 25 |
binding pocket | 25 |
force field | 25 |
peptide structures | 25 |
synthesized using | 25 |
highly selective | 25 |
tumor cell | 25 |
sequence data | 25 |
intracellular trafficking | 25 |
based therapeutics | 25 |
molecular biology | 25 |
activity towards | 25 |
fl peptide | 25 |
bactericidal activity | 25 |
data categories | 25 |
terminal part | 25 |
bacterial membranes | 25 |
membrane curvature | 25 |
basis function | 25 |
also used | 25 |
protein data | 25 |
adaptive immune | 25 |
antibiotic resistance | 25 |
protein aggregation | 25 |
enzyme activity | 25 |
analyzed using | 25 |
phase transition | 24 |
combinatorial peptide | 24 |
lipid rafts | 24 |
protein expression | 24 |
peptide drugs | 24 |
dimensional structures | 24 |
precursor protein | 24 |
cell responses | 24 |
new generation | 24 |
cytoplasmic membrane | 24 |
click chemistry | 24 |
bovine serum | 24 |
inhibitory effect | 24 |
structural biology | 24 |
nmr spectra | 24 |
therapeutic peptides | 24 |
viral vectors | 24 |
will present | 24 |
clinical use | 24 |
venom peptide | 24 |
factor receptor | 24 |
highly potent | 24 |
protecting group | 24 |
biomedical applications | 24 |
trypsin inhibitor | 24 |
two distinct | 24 |
ms spectra | 24 |
frog amps | 24 |
confi rmed | 24 |
based drug | 24 |
acyl chain | 24 |
new insights | 24 |
cell epitope | 24 |
ic values | 24 |
active sites | 24 |
peptide interactions | 24 |
consensus sequence | 24 |
nuclear localization | 24 |
mass spectrometer | 24 |
viral rna | 24 |
mast cells | 23 |
gel phase | 23 |
virus replication | 23 |
ray diffraction | 23 |
trp residues | 23 |
peptide derivatives | 23 |
cationic peptide | 23 |
like proteins | 23 |
dynamic light | 23 |
skeletal muscle | 23 |
molecular recognition | 23 |
chemical properties | 23 |
carrier protein | 23 |
clinical trial | 23 |
studies showed | 23 |
successfully applied | 23 |
newly synthesized | 23 |
proteomic analysis | 23 |
fatty acid | 23 |
endoplasmic reticulum | 23 |
stapled peptides | 23 |
plasmid dna | 23 |
kcal mole | 23 |
prrp snpf | 23 |
echinoderm prrp | 23 |
acid peptide | 23 |
fibril formation | 23 |
polyethylene glycol | 23 |
specific peptide | 23 |
systemic administration | 23 |
assembled structures | 23 |
binding constants | 23 |
model systems | 23 |
new analogues | 23 |
mediated delivery | 23 |
morpholino oligomers | 23 |
studies revealed | 23 |
structural similarity | 23 |
translational modification | 23 |
ebola virus | 23 |
also showed | 23 |
trimeric coiled | 23 |
polyacrylamide gel | 23 |
cell cultures | 23 |
antibacterial peptides | 23 |
specific peptides | 23 |
fi brils | 23 |
mass spectrum | 23 |
computational design | 22 |
analysis revealed | 22 |
native protein | 22 |
human protein | 22 |
peptide complexes | 22 |
reactive oxygen | 22 |
human genome | 22 |
mass spectrometric | 22 |
peptide conformation | 22 |
assay using | 22 |
tat peptide | 22 |
antisense oligonucleotides | 22 |
gh gl | 22 |
serum samples | 22 |
like receptor | 22 |
human serum | 22 |
peptide molecules | 22 |
coil structure | 22 |
tyrosine kinase | 22 |
three dimensional | 22 |
phosphorylation sites | 22 |
hemolytic activity | 22 |
method using | 22 |
active packaging | 22 |
red blood | 22 |
oxygen species | 22 |
antiproliferative activity | 22 |
antifungal proteins | 22 |
binding studies | 22 |
energy transfer | 22 |
healthy donors | 22 |
capsid protein | 22 |
heavy chain | 22 |
capsid proteins | 22 |
sh domains | 22 |
determined using | 22 |
human brain | 22 |
assembled peptide | 22 |
proline residues | 22 |
direct interaction | 22 |
high levels | 22 |
takes place | 22 |
duchenne muscular | 22 |
two decades | 22 |
fold higher | 22 |
transmembrane ot | 22 |
venom gland | 22 |
recently developed | 22 |
vero cells | 22 |
model peptide | 22 |
fluorescent protein | 22 |
synthesis using | 21 |
new method | 21 |
performance liquid | 21 |
three times | 21 |
exchange chromatography | 21 |
building block | 21 |
splice correction | 21 |
experimental conditions | 21 |
peptide nanostructures | 21 |
recently reported | 21 |
human amps | 21 |
protein targets | 21 |
much less | 21 |
based methods | 21 |
saccharomyces cerevisiae | 21 |
protein surface | 21 |
antibacterial properties | 21 |
free amino | 21 |
common ancestor | 21 |
tat protein | 21 |
electrostatic interaction | 21 |
vaccinia virus | 21 |
important roles | 21 |
virus fusion | 21 |
quantitative analysis | 21 |
blood vessels | 21 |
peptide corresponding | 21 |
immunomodulatory properties | 21 |
disulfide bridge | 21 |
sensing ion | 21 |
therapeutic target | 21 |
bacterial membrane | 21 |
cysteine proteases | 21 |
serum albumin | 21 |
related peptides | 21 |
fmoc tbu | 21 |
shared peptides | 21 |
physiological processes | 21 |
npf prrp | 21 |
antibody response | 21 |
dynamics simulation | 21 |
will also | 21 |
hiv infection | 21 |
proteolytic processing | 21 |
defi ned | 21 |
drug targets | 21 |
snpf prrp | 21 |
peptide may | 21 |
metal ion | 21 |
many different | 21 |
organic solvents | 21 |
hydrophobic content | 21 |
fusion inhibitor | 21 |
investigated using | 21 |
prion protein | 21 |
peptide protein | 21 |
peptide inhibitor | 21 |
peptide cleavage | 21 |
based drugs | 21 |
pro cleavage | 21 |
ii peptides | 21 |
two main | 21 |
peptides also | 21 |
snpf prrpr | 21 |
recombinant human | 21 |
using peptide | 21 |
may represent | 20 |
experimentally determined | 20 |
may play | 20 |
helical structures | 20 |
therapeutic applications | 20 |
two peptide | 20 |
structural motifs | 20 |
syncytial virus | 20 |
acetic acid | 20 |
acid side | 20 |
powerful tool | 20 |
binding constant | 20 |
mdx mice | 20 |
common cold | 20 |
bacterial growth | 20 |
proteolytic degradation | 20 |
ph range | 20 |
chemically synthesized | 20 |
cell division | 20 |
data analysis | 20 |
dna sequences | 20 |
also reported | 20 |
type glycoprotein | 20 |
last decade | 20 |
sheet structures | 20 |
viral genome | 20 |
fi nal | 20 |
expression system | 20 |
artifi cial | 20 |
chemical stability | 20 |
protein tyrosine | 20 |
results indicated | 20 |
human body | 20 |
resistant bacteria | 20 |
peripheral blood | 20 |
inflammatory responses | 20 |
genetically engineered | 20 |
gene encoding | 20 |
remains unclear | 20 |
analysis showed | 20 |
serum amyloid | 20 |
differential scanning | 20 |
i th | 20 |
antibody responses | 20 |
human host | 20 |
dipeptidyl peptidase | 20 |
membrane permeability | 20 |
display library | 20 |
past years | 20 |
peptide therapeutics | 20 |
cellular membranes | 20 |
peptide self | 20 |
virtual screening | 20 |
listeria monocytogenes | 20 |
experimentally validated | 20 |
lipid composition | 20 |
peptide synthesizer | 20 |
domain swapping | 20 |
peptide containing | 20 |
overlapping peptides | 20 |
coupling reaction | 20 |
major role | 20 |
protostome snpf | 20 |
antiviral activities | 20 |
different peptides | 20 |
protein coupled | 20 |
charged amino | 20 |
blood coagulation | 20 |
genes encoding | 20 |
bacillus subtilis | 20 |
terminal sequence | 20 |
respiratory syncytial | 20 |
may provide | 20 |
hydrophobic peptides | 19 |
inhibitory activities | 19 |
neutral ph | 19 |
angiotensin i | 19 |
plasmodium falciparum | 19 |
metal binding | 19 |
protein domains | 19 |
infected patients | 19 |
new peptides | 19 |
different peptide | 19 |
peptide chains | 19 |
releasing hormone | 19 |
oligomerization state | 19 |
type protein | 19 |
cancer therapy | 19 |
molecular dynamic | 19 |
biological fluids | 19 |
cystine knot | 19 |
neutrophil defensins | 19 |
fatty acids | 19 |
clinical studies | 19 |
basic amino | 19 |
previous work | 19 |
whole protein | 19 |
plant peptides | 19 |
like protein | 19 |
creatine kinase | 19 |
gold nanoparticles | 19 |
human alpha | 19 |
potent antimicrobial | 19 |
fpr alx | 19 |
chemical modification | 19 |
based approaches | 19 |
epidermal growth | 19 |
western blot | 19 |
helical peptide | 19 |
several studies | 19 |
allowed us | 19 |
expression systems | 19 |
peptides based | 19 |
hcmv infection | 19 |
catalytic efficiency | 19 |
using nmr | 19 |
peptides show | 19 |
peptide microarray | 19 |
viral load | 19 |
monte carlo | 19 |
epitope prediction | 19 |
shared tryptic | 19 |
quality control | 19 |
proteinase inhibitor | 19 |
virus binding | 19 |
peptides identified | 19 |
coat proteins | 19 |
viral infections | 19 |
fi eld | 19 |
energy minimization | 19 |
previous study | 19 |
large scale | 19 |
chemical modifications | 19 |
hydrophobic length | 19 |
skin secretions | 19 |
mesenchymal stem | 19 |
fold increase | 19 |
antiviral drugs | 19 |
see section | 19 |
structures formed | 19 |
phase method | 19 |
genome sequence | 19 |
formylpeptide receptor | 19 |
last years | 19 |
potent inhibitor | 19 |
salmonella typhimurium | 19 |
leader peptide | 19 |
tumour growth | 19 |
data points | 19 |
quantum dots | 19 |
web server | 19 |
peptides might | 19 |
another study | 19 |
opioid receptors | 19 |
simili swabs | 19 |
peptide fragment | 19 |
cleavage assay | 19 |
binding activity | 19 |
capillary electrophoresis | 18 |
functional protein | 18 |
alzheimer disease | 18 |
spike proteins | 18 |
haemolytic activity | 18 |
terminal peptide | 18 |
single peptide | 18 |
vascular endothelial | 18 |
paneth cell | 18 |
starting point | 18 |
head groups | 18 |
data suggest | 18 |
several peptides | 18 |
virus particles | 18 |
dna fragments | 18 |
type receptor | 18 |
relatively small | 18 |
immune cells | 18 |
structural properties | 18 |
cysteine protease | 18 |
extracellular domain | 18 |
signalling pathways | 18 |
peptide analogs | 18 |
targeted delivery | 18 |
will allow | 18 |
mature peptide | 18 |
protein fragments | 18 |
animal model | 18 |
peptide chemistry | 18 |
rna interference | 18 |
structural proteins | 18 |
peptide peaks | 18 |
proteins containing | 18 |
rich domains | 18 |
cell migration | 18 |
described previously | 18 |
heat shock | 18 |
protein concentration | 18 |
binding affinities | 18 |
analysis using | 18 |
ex vivo | 18 |
amyloid peptide | 18 |
bound peptides | 18 |
cellular functions | 18 |
hepg cells | 18 |
terminal residues | 18 |
affinity binding | 18 |
isoelectric point | 18 |
pdb id | 18 |
sa short | 18 |
binding assays | 18 |
binding free | 18 |
fpr agonists | 18 |
flow cytometry | 18 |
scoring function | 18 |
bacterial pathogens | 18 |
blood glucose | 18 |
hek cells | 18 |
using different | 18 |
peptide family | 18 |
hairpin structure | 18 |
higher affinity | 18 |
four peptides | 18 |
similar results | 18 |
therapeutic strategies | 18 |
low ph | 18 |
binding mode | 18 |
sequence identity | 18 |
interacting proteins | 18 |
inhibit hiv | 18 |
years ago | 18 |
high performance | 18 |
acidic ph | 18 |
lipid transfer | 18 |
results provide | 18 |
also shown | 18 |
new approach | 18 |
peptides will | 18 |
iia peptide | 18 |
human igg | 18 |
carcinogenic cells | 18 |
covalently linked | 18 |
inhibitory concentration | 18 |
hvr epb | 18 |
novel coronavirus | 18 |
fluorescently labeled | 18 |
membrane binding | 18 |
conformational studies | 18 |
food intake | 18 |
lif detection | 18 |
displayed peptide | 18 |
lipid molecules | 18 |
specific antibody | 18 |
directed evolution | 18 |
corresponding peptide | 18 |
peptide bonds | 17 |
untreated cells | 17 |
biophysical properties | 17 |
echinoderm receptors | 17 |
gene silencing | 17 |
authors declare | 17 |
antiviral effects | 17 |
atomic force | 17 |
several different | 17 |
rich peptide | 17 |
different strategies | 17 |
neuronal cells | 17 |
bodily fluids | 17 |
structural data | 17 |
total number | 17 |
protein levels | 17 |
low levels | 17 |
growth factors | 17 |
flight mass | 17 |
conformational properties | 17 |
also present | 17 |
molecular targets | 17 |
flow rate | 17 |
peptide mapping | 17 |
clinical isolates | 17 |
viral protein | 17 |
high efficiency | 17 |
array membrane | 17 |
peptide docking | 17 |
fusion inhibitors | 17 |
protein ligation | 17 |
inhibitory effects | 17 |
force microscopy | 17 |
nucleocapsid protein | 17 |
endothelial growth | 17 |
envelope proteins | 17 |
homology modeling | 17 |
tof mass | 17 |
coil peptide | 17 |
using synthetic | 17 |
peptide database | 17 |
protein target | 17 |
support vector | 17 |
structural motif | 17 |
highly efficient | 17 |
based peptide | 17 |
transition temperature | 17 |
resonance energy | 17 |
mammalian cell | 17 |
negative organisms | 17 |
resistance mechanisms | 17 |
different cell | 17 |
protein misfolding | 17 |
binding affi | 17 |
positive control | 17 |
resistant staphylococcus | 17 |
swab samples | 17 |
two major | 17 |
complex peptide | 17 |
protein production | 17 |
peptides showed | 17 |
west nile | 17 |
triple helix | 17 |
enzymatic degradation | 17 |
also able | 17 |
gel filtration | 17 |
two proteins | 17 |
data obtained | 17 |
fluorescence spectroscopy | 17 |
shed light | 17 |
biological systems | 17 |
hepatocellular carcinoma | 17 |
peptide nanotubes | 17 |
disordered proteins | 17 |
nanomolar range | 17 |
bacterial strains | 17 |
new peptide | 17 |
pharmaceutical industry | 17 |
genetic engineering | 17 |
peptide antibiotic | 17 |
bioinformatics tools | 17 |
sheet structure | 17 |
islet amyloid | 17 |
nmr data | 16 |
amyloid polypeptide | 16 |
high concentration | 16 |
serine proteinases | 16 |
conformational transition | 16 |
sensory neurons | 16 |
peptides across | 16 |
cartridge replacement | 16 |
protein docking | 16 |
new therapeutic | 16 |
vitro studies | 16 |
controlled release | 16 |
statistical analysis | 16 |
profi le | 16 |
fourier transform | 16 |
inflammatory cytokines | 16 |
assembly process | 16 |
salmonella enterica | 16 |
amphipathic peptides | 16 |
acid derivatives | 16 |
frog peptides | 16 |
neuropeptide signalling | 16 |
vector machine | 16 |
phospholipid membranes | 16 |
protein molecules | 16 |
peptide variants | 16 |
snake venoms | 16 |
two classes | 16 |
expression levels | 16 |
resistant strains | 16 |
copy number | 16 |
negative charge | 16 |
reversed phase | 16 |
significant role | 16 |
body fluids | 16 |
function relationship | 16 |
envelope glycoprotein | 16 |
medicinal chemistry | 16 |
signaling pathway | 16 |
antibody binding | 16 |
specific protein | 16 |
carboxyl group | 16 |
cytotoxic activity | 16 |
human blood | 16 |
cholesterol conjugation | 16 |
micromolar range | 16 |
mm sodium | 16 |
myocardial infarction | 16 |
rationally designed | 16 |
lipid mixing | 16 |
antibacterial agents | 16 |
among others | 16 |
well plates | 16 |
molecular cloning | 16 |
outer leaflet | 16 |
natural antimicrobial | 16 |
peptide interaction | 16 |
human antimicrobial | 16 |
new drugs | 16 |
high molecular | 16 |
peptide fusion | 16 |
neutralizing epitope | 16 |
based epitope | 16 |
mediated endocytosis | 16 |
currently available | 16 |
supplemental table | 16 |
specific inhibitors | 16 |
based proteomics | 16 |
studies using | 16 |
membrane interaction | 16 |
sequence information | 16 |
acid analysis | 16 |
helicobacter pylori | 16 |
natural peptides | 16 |
ray structure | 16 |
confocal microscopy | 16 |
virion surface | 16 |
prepared using | 16 |
highly expressed | 16 |
using phage | 16 |
different mechanisms | 16 |
amphiphilic peptides | 16 |
new drug | 16 |
great potential | 16 |
cov spike | 16 |
detailed analysis | 16 |
binding assay | 16 |
viral dna | 16 |
cellular delivery | 16 |
crystalline phase | 16 |
phosphatidic acid | 16 |
cell signaling | 16 |
fmoc chemistry | 16 |
ion exchange | 16 |
steric hindrance | 16 |
novel approach | 16 |
activated protein | 16 |
hepg cell | 16 |
dystrophin expression | 16 |
complex biological | 16 |
develop new | 16 |
growth inhibition | 16 |
aided design | 16 |
inhibit viral | 16 |
data indicate | 16 |
expressed protein | 16 |
stable isotope | 16 |
success rate | 16 |
fluorescence microscopy | 16 |
arctium lappa | 16 |
dendritic cell | 16 |
binding domains | 16 |
conformational flexibility | 16 |
polypeptide chain | 16 |
molecular masses | 16 |
potent anti | 16 |
results demonstrate | 16 |
designed based | 16 |
evaluated using | 16 |
mhc class | 16 |
interfering rna | 16 |
helix formation | 15 |
aromatic amino | 15 |
amyloid fibril | 15 |
lg ml | 15 |
membrane bilayer | 15 |
endocytic pathways | 15 |
primary sequence | 15 |
bacterial infection | 15 |
viral peptide | 15 |
stationary phase | 15 |
cell monolayers | 15 |
antitumor activity | 15 |
proteolytic stability | 15 |
cells expressing | 15 |
peptide epitopes | 15 |
ot helices | 15 |
phosphate buffer | 15 |
activity studies | 15 |
ms detection | 15 |
cysteine proteinase | 15 |
von willebrand | 15 |
seminal plasma | 15 |
scanning electron | 15 |
serine proteinase | 15 |
viral diseases | 15 |
charged peptides | 15 |
frequently used | 15 |
binding partners | 15 |
kinetic parameters | 15 |
inflammatory diseases | 15 |
chemical shift | 15 |
one hand | 15 |
selected peptides | 15 |
also show | 15 |
clinical development | 15 |
fusion mechanism | 15 |
zeta potential | 15 |
rana box | 15 |
antifungal peptides | 15 |
vitro activity | 15 |
structural requirements | 15 |
protein peptide | 15 |
much lower | 15 |
associated coronavirus | 15 |
time pcr | 15 |
peptide nanoparticles | 15 |
deficient mice | 15 |
repeat proteins | 15 |
microwave assisted | 15 |
conformational preferences | 15 |
better understand | 15 |
basic research | 15 |
calculated using | 15 |
surface receptors | 15 |
least three | 15 |
different methods | 15 |
data sets | 15 |
small interfering | 15 |
functional proteins | 15 |
molecular weights | 15 |
high yield | 15 |
sodium channel | 15 |
successfully used | 15 |
binding kinetics | 15 |
different proteins | 15 |
new antimicrobial | 15 |
synthetic vaccines | 15 |
multiple sequence | 15 |
vivo efficacy | 15 |
tryptophan residues | 15 |
goat anti | 15 |
gpcr agonists | 15 |
currently used | 15 |
proteome analysis | 15 |
electron spin | 15 |
direct translocation | 15 |
like function | 15 |
ray scattering | 15 |
membrane interfaces | 15 |
also investigated | 15 |
entry inhibitor | 15 |
effi ciently | 15 |
nile virus | 15 |
high level | 15 |
terminal residue | 15 |
source data | 15 |
reverse transcription | 15 |
free radical | 15 |
limited number | 15 |
peptides present | 15 |
binding peptide | 15 |
alternative splicing | 15 |
amyloid beta | 15 |
four different | 15 |
proteins may | 15 |
structure analysis | 15 |
native state | 15 |
natural sources | 15 |
hydrophobic mismatch | 15 |
biofilm formation | 15 |
promising candidates | 15 |
single molecule | 15 |
hydroxyl group | 15 |
human defensins | 15 |
hiv gp | 15 |
proteolytic activity | 15 |
leucine zipper | 15 |
peptide isolated | 15 |
side reactions | 15 |
great interest | 14 |
coil peptides | 14 |
native structure | 14 |
amphibian skin | 14 |
helical antimicrobial | 14 |
conformational space | 14 |
nmr structure | 14 |
nicotinic acetylcholine | 14 |
confi guration | 14 |
major histocompatibility | 14 |
positive charges | 14 |
ic value | 14 |
mass spectra | 14 |
organic solvent | 14 |
peptide activity | 14 |
based design | 14 |
enveloped virus | 14 |
fusion domain | 14 |
folded proteins | 14 |
gastrointestinal tract | 14 |
peptide dendrimers | 14 |
peptide hormones | 14 |
arabidopsis thaliana | 14 |
time consuming | 14 |
vaccine candidates | 14 |
block oligonucleotides | 14 |
signal sequence | 14 |
new family | 14 |
peptide families | 14 |
tumor targeting | 14 |
host proteins | 14 |
longer peptides | 14 |
different lengths | 14 |
potentially useful | 14 |
acid delivery | 14 |
early stage | 14 |
bacterial cells | 14 |
residual infectivity | 14 |
scrambled peptide | 14 |
virus envelope | 14 |
based method | 14 |
possible role | 14 |
control peptide | 14 |
dna damage | 14 |
necrosis factor | 14 |
interfacial hydrophobicity | 14 |
fluorescence quenching | 14 |
plant amps | 14 |
cell response | 14 |
opioid peptides | 14 |
page gel | 14 |
drug target | 14 |
recently described | 14 |
trichogin ga | 14 |
control group | 14 |
recent reviews | 14 |
using standard | 14 |
aromatic rings | 14 |
catalytic site | 14 |
ad hvr | 14 |
may contribute | 14 |
recently shown | 14 |
protein families | 14 |
good agreement | 14 |
peptide fraction | 14 |
protein substrates | 14 |
also play | 14 |
highly active | 14 |
signalling systems | 14 |
peptide recognition | 14 |
matrix metalloproteinase | 14 |
human erythrocytes | 14 |
adverse effects | 14 |
receptor agonist | 14 |
influenza hemagglutinin | 14 |
shotgun proteomics | 14 |
living organisms | 14 |
structurally similar | 14 |
kinase activity | 14 |
cytokine production | 14 |
activity assay | 14 |
adhesion molecules | 14 |
different protein | 14 |
trifluoroacetic acid | 14 |
terminal end | 14 |
two domains | 14 |
relatively low | 14 |
combinatorial libraries | 14 |
simulated annealing | 14 |
functional domains | 14 |
useful tools | 14 |
ii peptide | 14 |
inclusion bodies | 14 |
cleavage specificity | 14 |
new type | 14 |
web portal | 14 |
delivery vectors | 14 |
alternative approach | 14 |
well established | 14 |
peptide production | 14 |
protein interfaces | 14 |
one way | 14 |
target effects | 14 |
close proximity | 14 |
designed peptides | 14 |
mouse models | 14 |
entry process | 14 |
ligand interactions | 14 |
tau protein | 14 |
plant defensins | 14 |
one peptide | 14 |
also performed | 14 |
many peptides | 14 |
ionization time | 14 |
tumour cells | 14 |
cell type | 14 |
divalent cations | 14 |
various diseases | 14 |
reporter gene | 14 |
significantly increased | 14 |
significantly reduced | 14 |
specific targeting | 14 |
spin labels | 14 |
ga iv | 14 |
diabetes mellitus | 14 |
lysis buffer | 14 |
important factor | 14 |
human breast | 14 |
human formyl | 14 |
binding modes | 14 |
molecular modelling | 14 |
native proteins | 14 |
peptide ligand | 14 |
morpholino oligomer | 14 |
bsp method | 14 |
physiological conditions | 14 |
past decade | 14 |
various biological | 14 |
vesicular stomatitis | 14 |
receptor antagonists | 14 |
early stages | 14 |
hydrophobic side | 14 |
solid state | 14 |
therapeutic index | 14 |
antagonistic activity | 14 |
designed protein | 14 |
receptor subtype | 14 |
human monoclonal | 14 |
hydrophilic residues | 14 |
drug administration | 14 |
calcium mobilization | 14 |
two novel | 14 |
bioactive peptide | 14 |
lung cancer | 14 |
covalently attached | 14 |
antimicrobial protein | 14 |
original peptide | 13 |
burdock root | 13 |
fluid phase | 13 |
organic molecules | 13 |
small number | 13 |
competitive inhibition | 13 |
helical wheel | 13 |
oral administration | 13 |
proteins using | 13 |
precursor proteins | 13 |
functional analysis | 13 |
wide spectrum | 13 |
structural characteristics | 13 |
proteomics data | 13 |
clinical application | 13 |
biological samples | 13 |
cell receptors | 13 |
helical content | 13 |
heterodimeric coiled | 13 |
using high | 13 |
small intestinal | 13 |
neutralizing antibody | 13 |
amp delivery | 13 |
gram positive | 13 |
solution structures | 13 |
acidic residues | 13 |
cystic fibrosis | 13 |
calcium ions | 13 |
domain ii | 13 |
stomatitis virus | 13 |
neutrophil elastase | 13 |
electric field | 13 |
great importance | 13 |
rna polymerase | 13 |
sequence alignments | 13 |
using circular | 13 |
complex mixtures | 13 |
driving force | 13 |
disulphide bonds | 13 |
hydrophobic pocket | 13 |
peptide complex | 13 |
fpr antagonists | 13 |
protein phosphorylation | 13 |
atopic dermatitis | 13 |
computational protein | 13 |
type neuropeptide | 13 |
antioxidant activity | 13 |
proteinase inhibitors | 13 |
scissile bond | 13 |
identified using | 13 |
substrate recognition | 13 |
rich antimicrobial | 13 |
kda protein | 13 |
free peptide | 13 |
novel therapeutic | 13 |
low toxicity | 13 |
two amino | 13 |
affi nities | 13 |
herpes virus | 13 |
high density | 13 |
systemic delivery | 13 |
membrane permeabilization | 13 |
fs capillary | 13 |
peptidase iv | 13 |
labeled peptides | 13 |
cell carcinoma | 13 |
large numbers | 13 |
computational tools | 13 |
cell penetration | 13 |
physical properties | 13 |
food packaging | 13 |
parent peptide | 13 |
bilayer thickness | 13 |
receptor protein | 13 |
water vapor | 13 |
published peptides | 13 |
peak areas | 13 |
inhibited hiv | 13 |
coding sequence | 13 |
role played | 13 |
dna polymerase | 13 |
cell invasion | 13 |
disordered regions | 13 |
particle size | 13 |
enzymatic hydrolysis | 13 |
receptor antagonist | 13 |
positive organisms | 13 |
small size | 13 |
may result | 13 |
therapeutic drugs | 13 |
like particle | 13 |
tertiary structures | 13 |
containing mm | 13 |
carrier proteins | 13 |
cell receptor | 13 |
another approach | 13 |
synthetic vaccine | 13 |
increasing number | 13 |
stranded dna | 13 |
research group | 13 |
therapeutic use | 13 |
cells via | 13 |
viral particles | 13 |
anticancer activity | 13 |
scorpion venoms | 13 |
diseases including | 13 |
protein mixtures | 13 |
receptor activation | 13 |
single chain | 13 |
helix motif | 13 |
relationship studies | 13 |
conserved across | 13 |
formic acid | 13 |
binding specificity | 13 |
transmembrane region | 13 |
promising results | 13 |
antibody fragment | 13 |
ca binding | 13 |
high potential | 13 |
fl ow | 13 |
considerable interest | 13 |
two types | 13 |
hydrophobic surfaces | 13 |
chemotactic activity | 13 |
hcmv gb | 13 |
airway epithelial | 13 |
data show | 13 |
concentration range | 13 |
ot helix | 13 |
higher concentrations | 13 |
transduction pathways | 13 |
research groups | 13 |
uorescence spectroscopy | 13 |
nk cells | 13 |
vast majority | 13 |
experiments showed | 13 |
graduate school | 13 |
rna viruses | 13 |
different stages | 13 |
protein interface | 13 |
protein evolution | 13 |
urgent need | 13 |
barr virus | 13 |
zona pellucida | 13 |
commonly found | 13 |
bacterial species | 13 |
novo designed | 13 |
peptides targeting | 13 |
surface charge | 13 |
million people | 13 |
tropic hiv | 13 |
protein family | 13 |
ischemia reperfusion | 13 |
promising approach | 13 |
provide new | 13 |
willebrand factor | 13 |
ubiquitin ligases | 13 |
inhibition assays | 13 |
tissue engineering | 13 |
protein transduction | 13 |
less effective | 13 |
heptad repeats | 13 |
studies demonstrated | 13 |
physiological ph | 13 |
conserved among | 13 |
binding strength | 13 |
vice versa | 13 |
headgroup region | 13 |
structure activity | 13 |
achieved using | 13 |
tyrosine kinases | 13 |
blood plasma | 13 |
like serine | 13 |
based statistical | 13 |
low concentration | 13 |
small peptide | 13 |
peptide concentrations | 13 |
extensively studied | 13 |
transgenic mice | 13 |
highly effective | 13 |
low micromolar | 13 |
stop codon | 13 |
one another | 13 |
neural network | 13 |
human papillomavirus | 13 |
water interface | 13 |
tissue culture | 13 |
hydrophobicity scale | 12 |
human health | 12 |
type precursors | 12 |
prolyl oligopeptidase | 12 |
derived antimicrobial | 12 |
malaria vaccine | 12 |
particular interest | 12 |
hydrophobic surface | 12 |
nitric oxide | 12 |
based assays | 12 |
subcellular localization | 12 |
bacterial resistance | 12 |
oral bioavailability | 12 |
aromatic ring | 12 |
physiological substrates | 12 |
free energies | 12 |
peptide machines | 12 |
cell biology | 12 |
bronchoalveolar lavage | 12 |
assembling peptides | 12 |
may act | 12 |
ns protease | 12 |
high purity | 12 |
purified using | 12 |
membrane receptors | 12 |
phase i | 12 |
pharmacological properties | 12 |
two new | 12 |
new anti | 12 |
natural peptide | 12 |
transmembrane protein | 12 |
important step | 12 |
tumor necrosis | 12 |
health problem | 12 |
svm models | 12 |
uptake mechanism | 12 |
structural stability | 12 |
results will | 12 |
developed using | 12 |
causative agent | 12 |
well plate | 12 |
protected amino | 12 |
also identified | 12 |
binding region | 12 |
present paper | 12 |
identified peptides | 12 |
coil binding | 12 |
secondary structural | 12 |
binding capacity | 12 |
membrane dehydration | 12 |
cationic host | 12 |
molecular evolution | 12 |
peptides used | 12 |
results revealed | 12 |
high stability | 12 |
histocompatibility complex | 12 |
lipid interactions | 12 |
ms peak | 12 |
comparative analysis | 12 |
targeting peptide | 12 |
sodium phosphate | 12 |
database search | 12 |
human cancer | 12 |
peptides displayed | 12 |
detection system | 12 |
without affecting | 12 |
alpha helices | 12 |
structurally characterized | 12 |
charged lipids | 12 |
covalent attachment | 12 |
experimental results | 12 |
indicator peptides | 12 |
serum stability | 12 |
peptides obtained | 12 |
residues within | 12 |
phosphate groups | 12 |
salt concentration | 12 |
antimicrobial agent | 12 |
reported previously | 12 |
chikv infection | 12 |
type peptide | 12 |
activity spectrum | 12 |
another example | 12 |
may allow | 12 |
assisted solid | 12 |
potential use | 12 |
infectious disease | 12 |
based nanoparticles | 12 |
efficient gene | 12 |
already known | 12 |
negative control | 12 |
mechanical properties | 12 |
aminoisobutyric acid | 12 |
human umbilical | 12 |
plasma samples | 12 |
standard fmoc | 12 |
quantitative structure | 12 |
human fpr | 12 |
vivo delivery | 12 |
resistance genes | 12 |
energy change | 12 |
endothelial cell | 12 |
surface antigen | 12 |
play important | 12 |
defensin genes | 12 |
large amounts | 12 |
essential role | 12 |
predicted epitopes | 12 |
defense peptide | 12 |
current status | 12 |
dna sequence | 12 |
peptide based | 12 |
structural determinants | 12 |
combinatorial chemistry | 12 |
venom compounds | 12 |
inhibition activity | 12 |
aminohexanoic acid | 12 |
efficient delivery | 12 |
binding partner | 12 |
electrospray ionization | 12 |
infrared spectroscopy | 12 |
peptide stapling | 12 |
acidic conditions | 12 |
containing two | 12 |
amphipathic peptide | 12 |
cleavage products | 12 |
well understood | 12 |
short neuropeptide | 12 |
bioactive molecules | 12 |
cys residues | 12 |
respiratory tract | 12 |
forest virus | 12 |
molecule inhibitors | 12 |
methods used | 12 |
amps may | 12 |
multifunctional protein | 12 |
th validation | 12 |
novel class | 12 |
cell apoptosis | 12 |
conserved cysteine | 12 |
cell differentiation | 12 |
consensus clusters | 12 |
vivo study | 12 |
potential drug | 12 |
synthetic strategy | 12 |
five peptides | 12 |
integrin receptor | 12 |
hydrogen peroxide | 12 |
antimicrobial resistance | 12 |
recent work | 12 |
medical applications | 12 |
real time | 12 |
affinity maturation | 12 |
related proteins | 12 |
mycobacterium tuberculosis | 12 |
cytomegalovirus infection | 12 |
immature dendritic | 12 |
two methods | 12 |
using peptides | 12 |
enzyme inhibition | 12 |
containing peptide | 12 |
conformational epitopes | 12 |
mast cell | 12 |
sa aptamer | 12 |
affinity purification | 12 |
well documented | 12 |
drug resistant | 12 |
humoral immune | 12 |
small proteins | 12 |
rgd sequence | 12 |
spectrum activity | 12 |
labeled peptide | 12 |
showed high | 12 |
also applied | 12 |
recognition motif | 12 |
membrane destabilization | 12 |
aqueous media | 12 |
stapled peptide | 12 |
cd binding | 12 |
measured using | 12 |
cleavage assays | 12 |
different concentrations | 12 |
charged side | 12 |
delivery using | 12 |
human disease | 12 |
active peptide | 12 |
inhibitory properties | 12 |
cacybp sip | 12 |
inflammatory cytokine | 12 |
lipid nanoparticles | 12 |
antimicrobial drug | 12 |
venom toxins | 12 |
fmoc solid | 12 |
iii viral | 12 |
i will | 12 |
inflammatory mediators | 12 |
peptide hybrids | 12 |
basic protein | 12 |
glucose level | 12 |
repeat regions | 12 |
krsfiedllfnkv motif | 12 |
vivo experiments | 12 |
studies suggest | 12 |
stress conditions | 12 |
current study | 12 |
antiviral potency | 12 |
transmembrane domains | 12 |
cell lysis | 12 |
highly immunogenic | 12 |
cancer patients | 12 |
iii fusion | 12 |
carpet model | 12 |
novel human | 12 |
highly sensitive | 12 |
functional properties | 12 |
evidence suggests | 12 |
san diego | 12 |
synthetic biology | 12 |
complement system | 12 |
predicted peptides | 12 |
quaternary structure | 12 |
neurological symptoms | 11 |
well characterized | 11 |
soluble proteins | 11 |
significant differences | 11 |
mediated cell | 11 |
study also | 11 |
antifungal protein | 11 |
normal cells | 11 |
rat brain | 11 |
measles virus | 11 |
protein hydrolysate | 11 |
pharmacophore model | 11 |
high sensitivity | 11 |
environmental conditions | 11 |
insulin receptor | 11 |
may induce | 11 |
quantitative proteomics | 11 |
peptides within | 11 |
last two | 11 |
phage particles | 11 |
conjugated peptide | 11 |
anticancer drugs | 11 |
gnrh analogues | 11 |
cardiovascular disease | 11 |
increased resistance | 11 |
drosophila melanogaster | 11 |
electron density | 11 |
transfected cells | 11 |
delivery vehicles | 11 |
glycosylation sites | 11 |
contains two | 11 |
esr spectra | 11 |
taxonomic groups | 11 |
phylogenetic analysis | 11 |
low affinity | 11 |
intracellular targets | 11 |
consensus motif | 11 |
membrane interface | 11 |
bronchial epithelial | 11 |
based vaccines | 11 |
enzyme inhibitors | 11 |
molecular structure | 11 |
ii molecules | 11 |
complex protein | 11 |
fl exible | 11 |
genetically encoded | 11 |
reaction times | 11 |
fpr agonist | 11 |
simili swab | 11 |
muscle cells | 11 |
interacting peptides | 11 |
humoral response | 11 |
antimicrobial packaging | 11 |
hiv fusion | 11 |
ace inhibitors | 11 |
potential role | 11 |
well conserved | 11 |
functional group | 11 |
using molecular | 11 |
biological sciences | 11 |
less potent | 11 |
human salivary | 11 |
low temperatures | 11 |
cellular internalization | 11 |
antiviral peptide | 11 |
high propensity | 11 |
effi cacy | 11 |
will show | 11 |
inhibition assay | 11 |
surface protein | 11 |
activity profiling | 11 |
three classes | 11 |
dynamic simulations | 11 |
amber force | 11 |
inner membrane | 11 |
minimum inhibitory | 11 |
computational approaches | 11 |
also studied | 11 |
dna complexes | 11 |
fl uorinated | 11 |
culture medium | 11 |
data base | 11 |
low doses | 11 |
inclusion list | 11 |
natural product | 11 |
microbial infections | 11 |
peptides exhibited | 11 |
hinge region | 11 |
nmr structures | 11 |
guinea pig | 11 |
three independent | 11 |
breast milk | 11 |
coupling reagent | 11 |
therapeutic intervention | 11 |
effective mobilities | 11 |
coil region | 11 |
consensus sequences | 11 |
binding motifs | 11 |
site directed | 11 |
targeting peptides | 11 |
preliminary results | 11 |
supplementary table | 11 |
antibiotic activity | 11 |
new antibiotics | 11 |
fab library | 11 |
signalling system | 11 |
antiretroviral therapy | 11 |
key residues | 11 |
peptide drug | 11 |
pro residue | 11 |
mrna expression | 11 |
key step | 11 |
dissociation constants | 11 |
template surface | 11 |
carbon nanotubes | 11 |
partially folded | 11 |
antibody recognition | 11 |
cell survival | 11 |
fully understood | 11 |
chemical shifts | 11 |
gram negative | 11 |
myeloid cells | 11 |
spectrum antimicrobial | 11 |
receptor sequences | 11 |
false positive | 11 |
isoelectric focusing | 11 |
proteomics studies | 11 |
time scale | 11 |
adaptive immunity | 11 |
terminal cysteine | 11 |
microwave irradiation | 11 |
peptide aggregates | 11 |
protein microarrays | 11 |
cysteine residue | 11 |
small angle | 11 |
data category | 11 |
acids long | 11 |
peptides consisting | 11 |
ed peptides | 11 |
protein dynamics | 11 |
semliki forest | 11 |
target sites | 11 |
mdx mouse | 11 |
cd receptor | 11 |
spin label | 11 |
type gp | 11 |
receptor ccr | 11 |
rabbit antisera | 11 |
mm ammonium | 11 |
pna conjugates | 11 |
sci proc | 11 |
selective binding | 11 |
results also | 11 |
studies will | 11 |
tetrafl uoroborates | 11 |
wistar rats | 11 |
intestinal epithelial | 11 |
various cell | 11 |
validation model | 11 |
additional file | 11 |
extended conformation | 11 |
intravenous administration | 11 |
ionic interactions | 11 |
sequence motifs | 11 |
dynamic range | 11 |
peptide entry | 11 |
mm edta | 11 |
therapeutic molecules | 11 |
polar residues | 11 |
flexible docking | 11 |
complex model | 11 |
based protein | 11 |
amino terminus | 11 |
peptide showed | 11 |
transfection efficiency | 11 |
pattern recognition | 11 |
cell attachment | 11 |
catalytic triad | 11 |
structural dynamics | 11 |
pseudorabies virus | 11 |
study using | 11 |
single cell | 11 |
antiviral therapeutics | 11 |
binding energy | 11 |
human proteome | 11 |
beta peptide | 11 |
mainly due | 11 |
three main | 11 |
spin resonance | 11 |
results demonstrated | 11 |
pbs containing | 11 |
extensively used | 11 |
highest affinity | 11 |
many types | 11 |
caenorhabditis elegans | 11 |
secondary antibody | 11 |
asymmetric unit | 11 |
dpc micelles | 11 |
lc ms | 11 |
gene family | 11 |
fl exibility | 11 |
peptide mimics | 11 |
green fluorescent | 11 |
envelope glycoproteins | 11 |
built using | 11 |
study revealed | 11 |
multiple copies | 11 |
cationic cpps | 11 |
peptide produced | 11 |
integral membrane | 11 |
sars virus | 11 |
fusion loops | 11 |
fungal cell | 11 |
reaction mixture | 11 |
different amino | 11 |
amyloid fi | 11 |
localization signal | 11 |
cytoplasmic tail | 11 |
cho cells | 11 |
contained within | 11 |
membrane active | 11 |
surface proteins | 11 |
mobile phase | 11 |
conformational epitope | 11 |
ms acquisition | 11 |
peptide contains | 11 |
dimer interface | 11 |
studied using | 11 |
give rise | 11 |
dna gyrase | 11 |
extracellular loop | 11 |
cold allodynia | 11 |
inhibitory peptide | 11 |
frog skin | 11 |
local concentration | 11 |
phage displayed | 11 |
target specificity | 11 |
films incorporated | 11 |
based analysis | 11 |
nasal swab | 11 |
lc gradient | 11 |
model membrane | 11 |
studies indicate | 11 |
amyloid precursor | 11 |
proteins present | 11 |
peptide also | 11 |
corona virus | 11 |
family members | 11 |
electrostatic repulsion | 11 |
ischemic stroke | 11 |
structural elements | 11 |
protein stability | 11 |
high potency | 11 |
ray crystal | 11 |
skin secretion | 11 |
several proteins | 11 |
tyrosine residues | 11 |
previously shown | 11 |
structural differences | 11 |
leading cause | 11 |
long peptides | 11 |
pathogenic microorganisms | 11 |
coupling reactions | 11 |
synthesis method | 11 |
human skin | 11 |
transfer proteins | 11 |
widely distributed | 11 |
muscular atrophy | 11 |
amadori products | 11 |
venom components | 11 |
degradation products | 11 |
transmembrane helices | 11 |
several types | 11 |
positive selection | 11 |
synthetic analogues | 11 |
solution phase | 10 |
pp ab | 10 |
proline residue | 10 |
many amps | 10 |
generated using | 10 |
peptide thioester | 10 |
ms data | 10 |
lung epithelial | 10 |
infl ammatory | 10 |
also synthesized | 10 |
hydrophobic domains | 10 |
cell activation | 10 |
fi ndings | 10 |
targeted gene | 10 |
viral gene | 10 |
folded protein | 10 |
gp binding | 10 |
findings suggest | 10 |
brain tumors | 10 |
food preservation | 10 |
potential antimicrobial | 10 |
orthogonally protected | 10 |
also provides | 10 |
therapeutic agent | 10 |
samples containing | 10 |
peptide ligation | 10 |
protein recognition | 10 |
vitro evolution | 10 |
peptide samples | 10 |
sialic acid | 10 |
peptide exhibited | 10 |
containing amino | 10 |
secondary metabolites | 10 |
uv cd | 10 |
membranotropic sequences | 10 |
cells infected | 10 |
vector machines | 10 |
spinal cord | 10 |
drug molecules | 10 |
buforin ii | 10 |
ace binding | 10 |
functional site | 10 |
platelet activation | 10 |
peptide antimicrobial | 10 |
content mixing | 10 |
endogenous peptide | 10 |
helical bundle | 10 |
peptides bind | 10 |
negative curvature | 10 |
designed peptide | 10 |
translocation across | 10 |
general formula | 10 |
phage particle | 10 |
inhibitory protein | 10 |
antimicrobial proteins | 10 |
viral glycoproteins | 10 |
turn structure | 10 |
significant reduction | 10 |
nmr experiments | 10 |
recently published | 10 |
umbilical vein | 10 |
key roles | 10 |
growing interest | 10 |
three types | 10 |
transform infrared | 10 |
three distinct | 10 |
protein will | 10 |
antiviral agents | 10 |
antiviral therapy | 10 |
peptide amphiphile | 10 |
purified virus | 10 |
ms method | 10 |
metabolic pathways | 10 |
structural similarities | 10 |
electrophoretic mobility | 10 |
mutagenesis studies | 10 |
amphipathic helix | 10 |
lactic acid | 10 |
tumor angiogenesis | 10 |
specific amino | 10 |
interacting partners | 10 |
infarct size | 10 |
amyloid plaques | 10 |
increasing concentrations | 10 |
open reading | 10 |
cleavage activity | 10 |
matrix protein | 10 |
tissue damage | 10 |
amphipathic helical | 10 |
hiv activity | 10 |
spot synthesis | 10 |
carbon atoms | 10 |
new york | 10 |
peptides inhibit | 10 |
significantly higher | 10 |
scrambled peptides | 10 |
may help | 10 |
correlation spectroscopy | 10 |
suffi cient | 10 |
based delivery | 10 |
lipid vesicles | 10 |
inhibitory potency | 10 |
molecular characterization | 10 |
affinity tags | 10 |
disease progression | 10 |
affinity selection | 10 |
recent developments | 10 |
lysine residue | 10 |
modified peptide | 10 |
cyclic rgd | 10 |
therapeutic efficacy | 10 |
phosphorylated peptides | 10 |
food industry | 10 |
biological evaluation | 10 |
lipid peroxidation | 10 |
lower concentrations | 10 |
resin using | 10 |
well studied | 10 |
pancreatic polypeptide | 10 |
phase chemistry | 10 |
drug leads | 10 |
like protease | 10 |
neuronal death | 10 |
physiological functions | 10 |
peptide gene | 10 |
dipolar cycloaddition | 10 |
escape mutations | 10 |
acid substitution | 10 |
biotechnological applications | 10 |
coli strain | 10 |
comparative study | 10 |
extended chain | 10 |
rough surface | 10 |
will lead | 10 |
scale production | 10 |
peptide segments | 10 |
lipid head | 10 |
manually curated | 10 |
point mutation | 10 |
membrane translocation | 10 |
natural substrate | 10 |
protein conformation | 10 |
connectin titin | 10 |
beta defensin | 10 |
peptide antibiotics | 10 |
covalent conjugation | 10 |
protein analysis | 10 |
insect cells | 10 |
ang i | 10 |
dynamics calculations | 10 |
protein fold | 10 |
receptor tyrosine | 10 |
regulatory peptides | 10 |
processes including | 10 |
acquired resistance | 10 |
amersham biosciences | 10 |
blood samples | 10 |
residues located | 10 |
single transmembrane | 10 |
human coronavirus | 10 |
using either | 10 |
xenopus laevis | 10 |
conformationally constrained | 10 |
public health | 10 |
opioid peptide | 10 |
silver nanoparticles | 10 |
may cause | 10 |
culture media | 10 |
amphibian antimicrobial | 10 |
nerve growth | 10 |
significantly improved | 10 |
high specificity | 10 |
will describe | 10 |
experimental evidence | 10 |
low abundance | 10 |
following treatment | 10 |
healthy cells | 10 |
protein association | 10 |
dimerization domain | 10 |
selective pressure | 10 |
rapid identification | 10 |
hiv vaccine | 10 |
cysteine proteinases | 10 |
like activity | 10 |
correlation coefficient | 10 |
free radicals | 10 |
obtained using | 10 |
neutralizing human | 10 |
hydrophobic region | 10 |
viral capsid | 10 |
regulatory proteins | 10 |
times higher | 10 |
phase high | 10 |
single protein | 10 |
obtained results | 10 |
related diseases | 10 |
virus hemagglutinin | 10 |
using solid | 10 |
antiviral properties | 10 |
positive strains | 10 |
aureus strains | 10 |
terminal peptides | 10 |
intravenous injection | 10 |
two groups | 10 |
forming peptide | 10 |
may affect | 10 |
high sequence | 10 |
domain iii | 10 |
gp fusion | 10 |